HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a neutral rating on Zymeworks (NASDAQ:ZYME) and maintained an $8 price target.
August 15, 2023 | 11:14 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zymeworks' stock rating has been reiterated as neutral by HC Wainwright & Co. with a maintained price target of $8.
The reiteration of a neutral rating indicates that the analyst does not foresee significant price movement in the near term. The maintained price target of $8 also suggests that the analyst believes the stock is fairly valued at its current price. This could lead to a neutral or stagnant short-term price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100